Belantamab Drug Asset Due Diligence Report 2026

This Belantamab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Belantamab can convert its Monoclonal antibody profile and BCMA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Belantamab (query alias: belantamab)
Modality / target	Monoclonal antibody; BCMA; BCMA inhibitors
Highest global status	Phase 1/2
Originator	GSK Plc
Active developers	GSK Plc, GlaxoSmithKline (China) Investment Co. Ltd., GlaxoSmithKline Research & Development Ltd.

The MCP disease footprint includes Refractory Multiple Myeloma, Multiple Myeloma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05714839	Phase 1/2	Recruiting	123	Part 1, 2 and 3: Number of Participants with any Adverse Event
NCT05145816	Phase 1/2	Recruiting	37	Safety/Tolerability as measured by number of subjects with dose limiting toxicity (Part 1)
NCT06413511	Phase 1	Withdrawn	Not disclosed	Number of participants with adverse events (AEs) and serious adverse events (SAEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA: RESULTS FROM PART 1 OF THE FIRST-IN-HUMAN PHASE 1/2 DREAMM-20 TRIAL

Phase 1/2; n=18; evaluation: Positive. Reported fields: ORR = 28 % ; ORR = 28 % ; ORR = 28 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Belantamab addresses Refractory Multiple Myeloma, Multiple Myeloma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 81 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: BCMA records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-09	Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases	Phase 3	Financial terms not disclosed
2026-05-28	智翔金泰就纬利妥米单抗注射液与药友制药达成大中华区独占授权合作，共拓肿瘤与自免疾病创新治疗蓝海	NDA/BLA	US$44.2M upfront; US$224.2M milestones; US$268.4M stated total
2026-05-14	Allogene Therapeutics ends China cell therapy deal with Overland	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination therapy with an anti BCMA antibody and a gamma secretase inhibitor”. The milestone feed surfaced a patent-application signal described as “Belantamab mafodotin in combination with pembrolizumab for treating cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO